TFF Pharmaceuticals receives additional funding from Leidos

TFF Pharmaceuticals (TFFP) announced that Leidos (LDOS) has awarded the Company additional funding under the DARPA Personalized Protective Biosystems program to develop next-generation countermeasures for military and healthcare personnel. "We are pleased with the continued advancement of this program and our relationship with Leidos," said Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals. "There is an unmet need to develop next-generation countermeasures to adequately protect our military and civilian populations. Our technology not only allows for delivery of various countermeasures to neutralize biochemical threats directly at the site of entry, but is also needle-free and temperature independent, making these countermeasures easily deployed and administered with ease for future biochemical threat preparedness and biodefense. We believe our Thin Film Freezing platform has extraordinary potential to improve upon numerous applications, including the development of the next generation of chemical and biological protective technologies that can significantly improve the level of protection for our military and front-line personnel."